First Trust NYSE Arca Biotechnology Index FundFBT:PCQ:USD

Add to portfolio
Compare
Interactive chart
Historical prices
View PDF
59.66
0.26 / 0.44%
40.48 - 61.53+0.74
Close in USDToday's change52-week range3-yr sharpe ratio
As of May 17 2013 20:59 BST.Data delayed by at least 15 minutes.

Interactive chart

ETF performance

Objective

The investment seeks investment results that correspond generally to the price and yield (before the fund's fees and expenses) of an equity index called the NYSE Arca Biotechnology Index(SM). The fund will normally invest at least 90% of its net assets plus the amount of any borrowings for investment purposes in common stocks that comprise the index. The index is an equal-dollar weighted index designed to measure the performance of a cross section of companies in the biotechnology industry that are primarily involved in the use of biological processes to develop products or provide services. The fund is non-diversified.

Profile

Fund typeOpen Ended Investment Company
Investment style (stocks)
Market Cap: Mid
Investment Style: Growth
Morningstar categoryHealth
Launch date19/06/2006
Price currencyUSD
DomicileUnited States
SymbolFBT
Manager & start date
Roger Testin
19/06/2006
Daniel Lindquist
19/06/2006
Jon Erickson
19/06/2006
David McGarel
19/06/2006
Stan Ueland
08/11/2006

Investment

Total net assets
327.25m USDAs of Apr 30 2013
Market cap343.05m USD
Shares outstanding5.75m
Average volume (10-day)54.75k
Net expense ratio0.60%
Last dividend--
Div yield0.00%
Div ex-date--
Div pay-date--
Available for saleMexico, United States

Diversification

Asset type

US stock
95.07%
Non-US stock
4.93%
Other
0.00%
Cash
0.00%
Bond
0.00%

Top 5 sectors

Healthcare
100.00%

Top 5 Regions

United States
95.07%
Eurozone
4.93%

Sector and region weightings are calculated using only long position holdings of the portfolio.

Sector & regional holdings

Top 5 holdings

Company1 year
change		Portfolio
weight		Long
allocation
Biogen Idec Inc
BIIB:NSQ		+70.72%6.14%
Gilead Sciences Inc
GILD:NSQ		+124.75%5.73%
Amgen Inc
AMGN:NSQ		+49.74%5.73%
Nektar Therapeutics, Inc.
NKTR:NSQ		+45.14%5.65%
Incyte Corp Ltd
INCY:NSQ		+4.40%5.60%
As of Mar 31 2013.Data delayed by at least 15 minutes.Top 10 holdings

The performance data shown in tables and graphs on this page is calculated in USD of the fund / index / average (as applicable), on a Bid To Bid / Nav to Nav basis, with gross dividends re-invested on ex-dividend date. Past performance is not necessarily a guide to future performance; unit prices may fall as well as rise.

All managed funds data located on FT.com is subject to the FT Terms & Conditions . All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.

All data shown on this page, unless noted otherwise is Data Source and Copyright: Morningstar, Inc. 2013
All Rights reserved

© 2013 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.

The Morningstar Equity Style Box is a unique graphical tool showing a fund’s true investment style and market capitalisation.

The Morningstar Fixed Income Style Box is a unique graphical tool showing a fund's true credit quality and duration.

Pricing for ETFs is the latest price and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.